Loading...

DRREDDY Dr Reddys Laboratories Ltd Quarterly Earnings Reports Announcement

Dr R

DRRD

Dr Reddys Laboratories Ltd

(DRREDDY)

2025 Announcement

US FDA inspection

Analyst / Institutional Mee...

Sustainability targets / ESG

Equity Investment

Exclusive licensing deal

Investor Meeting

Analyst Investor Meet

GST tax dispute

GST tax penalty order

Regulatory approval

Analyst / Investor Meet

Loss of share certificates

Analyst / Institutional Mee...

US FDA inspection – no obse...

Cybersecurity incident

Management Change

Share Certificate Loss

Earnings Call Transcript

Regulatory Compliance

Financial Results Publication

Earnings Call Recordings

Management Update

Investor Presentation

Financial Results Q2

Financial Results Update

USFDA Inspection Outcome

Regulatory Disclosure

Earnings Call Update

Share Transfer Update

Biosimilar Approval

Newspaper Publication

Share Transfer Update

New Product Launch

USFDA Inspection Update

STUGERON Acquisition

FDA Inspection Results

Share Transfer Update

Penalty Order Received

Analyst Meet Scheduled

Management Change

Tax Reassessment Stay

Share Transfer Window

Loss of Share Certificates

Analyst Meeting

Investor Meet Scheduled

USFDA Inspection Update

Subsidiary Dissolution

Newspaper Publication

Q1 FY26 Earnings

Stake Acquisition

Management Change

Director Re-appointment

Financial Results

Earnings Call Recording

New Auditors Appointment

Q1 FY26 Results

FDA Inspection Update

Share Transfer Notice

FDA Inspection Result

FDA Inspection Results

Earnings Call Announcement

Compliance Certificate

Investor Meetings

Dividend Tax Notice

Investor Meet Scheduled

Annual Report Filed

Investor Meetings

Biosimilar Collaboration

Equity Share Allotment

Tax Notice Update

Share Certificate Loss

Share Certificate Loss

Unclaimed Dividends

Annual Compliance Report

USFDA Inspection

Investor Meetings

Earnings Call Update

Investor Meetings

Financial Results Published

Earnings Call Audio

New Subsidiary Created

New Subsidiary in Vietnam

Employee Stock Options

Appointment of Auditor

Management Change

Earnings Call Announcement

Share Certificate Loss

Market Speculation

Workforce Cost Clarification

Tax Notice Received

Compliance Certificate

Subsidiary Sale

Share Certificate Loss

Investor Meeting

Tax Demand Order

FDA Inspection Update

Tax Demand Order

Investor Meet Schedule

Share Certificates Notice

Licensing Agreement

Investor Meeting Scheduled

Investor Meeting Scheduled

Investor Meetings

Tax Penalty Notification

GST Penalty Announcement

Strong Earnings Growth

Investor Meeting Scheduled

SEC Filing Update

Financial Results Publication

Earnings Call Recording

Lawsuit Disclosure

Earnings Call Notice

Subsidiary Sale

Compliance Certificate

Credit Rating Reaffirmed

New Subsidiary in Finland

ESOP Share Allotment

Regulatory Penalty

Tax Penalty Disclosure

Investor Meeting Scheduled

Regulatory fines

Toripalimab Launch

Regulatory Fine Notice

Investor Meeting

Investor Meeting

Investor Meetings

USFDA Inspection Results

Credit Rating Update

Product Recall Clarification

Share Certificate Notice

Regulatory Penalty Imposed

Earnings Call Update

Quarterly Filing

Investor Meeting

Financial Results Q2

Earnings Call Update

Financial Results

Stock Options Granted

Stock Split Update

New Drug Launch

Earnings Call Announcement

Subsidiary Liquidation

CAR-T Trial Results

Compliance Certificate

New Subsidiary Launch

Licensing Agreement

Subsidiary Dissolution

Acquisition Completed

Acquisition Update

Regulatory Penalty

USFDA Inspection Update

Lost Share Certificates

Investor Meeting

Clarification Announcement

USFDA Inspection Update

China Regulatory Action

Investor Meeting

FDA Inspection Results

Tax Demand Order

USFDA Inspection Update

Equity shares allotted unde...

Dr. Reddys Share Certificates

Investor Meeting

Earnings Call Outcomes

Disclosure of investment in JV

Investment in Clean Renewab...

Joint Venture Update

Advertisement of Financial ...

Financial Results and Equit...

Financial Results and Equit...

Investor Meet - Conference ...

Tax Demand Order

Earnings Call Announcement

Acquisition Announcement

Certificate Confirmation

Licensing Agreement Announc...

Investor Call Audio Recording

Acquisition Announcement

Investor Conference Partici...

Newspaper Advertisement

Investor Conference Partici...

Analyst/Investor Meeting In...

Analyst Meeting Intimation

Equity Shares Allotment

Notice of Loss of Share Cer...

Tax Demand Order

Quarterly Report Filing

License Agreement for Cyclo...

Investor Conference Partici...

Clarification Announcement

USFDA Inspection

ICRA Credit Ratings Reaffirmed

Investor Meeting

Aurigene Facility Opening

Equity Shares Allotted

Newspaper Publication

Acquisition Update

Compliance Report Submission

Investor Conference

Tax Demand Order

Investment Update

Distribution Agreement

Tax Demand Order

Tax Demand Order with Penalty

Loss of Share Certificates

GMP Inspection Completion

Investor Conferences

Investor Conferences

Earnings Call Transcript

Penalty Reduction

Financial Results Publication

Change in Management

Financial Results, CFO Change

Employee Stock Options

Tax Demand Order

Change in Management

Joint Venture Announcement

Joint Venture and Managemen...

Voluntary Recall

USFDA Response Letter

Certificate Filing

Earnings Call Intimation

Stake Sale Announcement

Newspaper Publication

Compliance Certificate

Marketing Agreement

Certificate Confirmation

Partnership Announcement

Licensing Agreement

Allotment of ESOP

Incorporation of Subsidiary

Penalty Announcement

Tax Demand Order

Tax Demand Order

Share Certificate Loss

Analyst Meeting

Lawsuit Allegations

Investor Meeting

Investor Conferences

Tax Litigation Order

Analyst Meet Intimation

Equity Shares Allotted to E...

Tax Demand Order from GST A...

Clarification on Speculation

Notice of Loss of Share Cer...

Update on USFDA Inspection

Update on USFDA Inspection

Earnings call transcript re...

Investor Meetings

Filing of Form 6-K

Quarterly Earnings

Investment and Liquidation

Grant of Employee Stock Opt...

Postal Ballot Notice

Denial of Acquisition Rumors

Tax Demand Order

Postal Ballot Notice for Ap...

Share Certificates Lost

Management Changes

Recall Clarification

Tax Demand Order

Confirmation Certificate Re...

Regulatory Action: Tax Dema...

Tax Demand Order

Appointment of Director

Acquisition of Edity Therap...

Loss of Share Certificates

Sustainability Recognition

Equity Shares Allotment

Inspection Completion

Inspection at R&D Facility

Collaboration for ALS treat...

Investor Conference

Investor Conference

Share Certificate Loss Notice

Equity Shares Allotment

Analyst/Investor Meet

Investor Conferences

Acquisition of O2 Renewable...

Litigation Allegation

Equity Shares Allotment

Filing of Form 6-K

Financial Results Publication

Earnings Call Audio Recordings

US FDA Inspection

Financial Results Announcement

Stock Options Grant

Advertisement Publication

Inspection Completed

Litigation Allegations

Certificate Confirmation

Incorporation of subsidiary

Incorporation of Subsidiary

Appointment of Additional D...

Disclosure of Event

Loss of Share Certificates ...

Participation in Conference

Allotment of Equity Shares ...

Cancellation of Certificate...

Loss of Share Certificates

Allotment of Equity Shares

Participation in Investor C...

New Product Launches

Conference Participation

Post-Market Surveillance

Stock Options Allotment

Financial Statements

Financial Statements

Earnings Guidance

Retirement, Resignation

Financial Statements

Retirement of Director, Cha...

Merger of Equals

Routine Inspection - Zero O...

Financial Statements

Equity, Debt, VC, Private E...

Application Accepted for Re...

Financial Statements, Earni...

Dismissing Shareholders

Investor Meetings

Product Expansion

Equity Offerings

Contract Renewal

Voluntary Action Indicated ...

Financial Statements

Participation in Investor C...

Divestment of Assets

New Product Launches

Stock Option allotment

Conference Participation

Regulation Compliance

Investor Meetings

Pre-Approval Inspection and...

Product-specific inspection...

Financial Statements

Routine inspection with obs...

New Product Launches

New Product Launches

External Links:

Data:

Dr. Reddy's Laboratories approved its unaudited financial results for the quarter and half-year ended September 30, 2025, showing revenues of 88,051 million and profit of 14,268 million.

AI Assistant

Dr Reddys Laboratories Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.